We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Bioventus (BVS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Bioventus is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Bioventus is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BVS' full-year earnings has moved 1.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BVS has moved about 93.3% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.6% on a year-to-date basis. This means that Bioventus is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Amneal Pharmaceuticals (AMRX - Free Report) . The stock is up 42.1% year-to-date.
For Amneal Pharmaceuticals, the consensus EPS estimate for the current year has increased 2.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Bioventus belongs to the Medical - Drugs industry, a group that includes 136 individual companies and currently sits at #102 in the Zacks Industry Rank. Stocks in this group have gained about 2.3% so far this year, so BVS is performing better this group in terms of year-to-date returns. Amneal Pharmaceuticals is also part of the same industry.
Bioventus and Amneal Pharmaceuticals could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Bioventus (BVS - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Bioventus is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Bioventus is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BVS' full-year earnings has moved 1.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, BVS has moved about 93.3% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.6% on a year-to-date basis. This means that Bioventus is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Amneal Pharmaceuticals (AMRX - Free Report) . The stock is up 42.1% year-to-date.
For Amneal Pharmaceuticals, the consensus EPS estimate for the current year has increased 2.7% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Bioventus belongs to the Medical - Drugs industry, a group that includes 136 individual companies and currently sits at #102 in the Zacks Industry Rank. Stocks in this group have gained about 2.3% so far this year, so BVS is performing better this group in terms of year-to-date returns. Amneal Pharmaceuticals is also part of the same industry.
Bioventus and Amneal Pharmaceuticals could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.